These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 32727835)

  • 1. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
    Bar-Or A; Calkwood JC; Chognot C; Evershed J; Fox EJ; Herman A; Manfrini M; McNamara J; Robertson DS; Stokmaier D; Wendt JK; Winthrop KL; Traboulsee A
    Neurology; 2020 Oct; 95(14):e1999-e2008. PubMed ID: 32727835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
    Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
    Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
    Kaufman M; Pardo G; Rossman H; Sweetser MT; Forrestal F; Duda P
    J Neurol Sci; 2014 Jun; 341(1-2):22-7. PubMed ID: 24731783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
    Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
    Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
    Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
    Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
    Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
    Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
    Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
    Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Baine Y; Cheuvart B; Silerova M; Mesaros N
    Hum Vaccin Immunother; 2019; 15(2):327-338. PubMed ID: 30252603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.
    Lorefice L; Mellino P; Frau J; Coghe G; Fenu G; Cocco E
    Neurol Sci; 2024 Aug; 45(8):3951-3959. PubMed ID: 38472551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
    Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
    Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
    Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
    Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Hahn N
    Neurology; 2021 May; 96(18):870. PubMed ID: 34032592
    [No Abstract]   [Full Text] [Related]  

  • 15. Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Bar-Or A; Herman A; Stokmaier D
    Neurology; 2021 May; 96(18):870. PubMed ID: 34032593
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.
    Brodmerkel C; Wadman E; Langley RG; Papp KA; Bourcier M; Poulin Y; Ho V; Guenther L; Kunynetz R; Nigen S; Vender R; Wasel N; Hsu MC; Szapary P
    J Drugs Dermatol; 2013 Oct; 12(10):1122-9. PubMed ID: 24085047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
    Buttery JP; Riddell A; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Harnden A; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
    JAMA; 2005 Apr; 293(14):1751-8. PubMed ID: 15827314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.
    Gomez EV; Bishop JL; Jackson K; Muram TM; Phillips D
    BioDrugs; 2017 Dec; 31(6):545-554. PubMed ID: 29116597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects.
    Tay L; Leon F; Vratsanos G; Raymond R; Corbo M
    Arthritis Res Ther; 2007; 9(2):R38. PubMed ID: 17425783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
    Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
    Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.